H.C. Wainwright analyst Joseph Pantginis downgraded BiomX to Neutral from Buy. BiomX has "had a rough time as of late," says the analyst, who notes that both the CEO and Chairman of the Board resigned from the company on March 6, adding "further concern about the potential path forward for the company."
